Travere Therapeutics (TVTX) Assets (2011 - 2026)
Travere Therapeutics posted quarterly Assets of $555.2 million for Q1 2026, up 1.16% year-on-year from $548.8 million in Q1 2025, and down 8.26% on a QoQ basis from $605.2 million in Q4 2025.
Travere Therapeutics (TVTX) has 16 years of Assets data on file, last reported at $555.2 million in Q1 2026.
- For the quarter ending Q1 2026, Assets rose 1.16% year-over-year to $555.2 million; the trailing twelve-month figure through Mar 2026 stood at $555.2 million (up 1.16% YoY), and the FY2025 full-year result was $605.2 million, up 1.86% from the prior year.
- Assets for Q1 2026 stood at $555.2 million, down from $605.2 million in the prior quarter.
- Across five years, Assets topped out at $832.8 million in Q3 2023 and bottomed at $504.4 million in Q3 2024.
- The 5-year median for Assets is $663.5 million (2024), against an average of $664.1 million.
- The widest annual swing landed in 2023, when Assets advanced 17.3%; it then tumbled 39.44% in 2024.
- A 5-year view of Assets shows it stood at $672.6 million in 2022, then increased by 17.3% to $788.9 million in 2023, then retreated by 24.69% to $594.1 million in 2024, then rose by 1.86% to $605.2 million in 2025, then declined by 8.26% to $555.2 million in 2026.
- The last three Assets figures came in at $555.2 million (Q1 2026), $605.2 million (Q4 2025), and $538.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 14.93 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 37.37 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.73 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 78.88 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 33.89 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 26.48 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 23.64 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 40.87 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 5.13 Bn |
| 10 | Travere Therapeutics | 4.34 Bn | 4.26 Bn | 102.38 Mn | 555.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 555.19 Mn |
| Dec 31, 2025 | 605.19 Mn |
| Sep 30, 2025 | 538.58 Mn |
| Jun 30, 2025 | 555.31 Mn |
| Mar 31, 2025 | 548.80 Mn |
| Dec 31, 2024 | 594.13 Mn |
| Sep 30, 2024 | 504.41 Mn |
| Jun 30, 2024 | 551.12 Mn |
| Mar 31, 2024 | 663.55 Mn |
| Dec 31, 2023 | 788.91 Mn |
| Sep 30, 2023 | 832.85 Mn |
| Jun 30, 2023 | 736.43 Mn |
| Mar 31, 2023 | 808.23 Mn |
| Dec 31, 2022 | 672.59 Mn |
| Sep 30, 2022 | 726.22 Mn |
| Jun 30, 2022 | 779.49 Mn |
| Mar 31, 2022 | 828.41 Mn |
| Dec 31, 2021 | 776.63 Mn |
| Sep 30, 2021 | 775.08 Mn |
| Jun 30, 2021 | 746.77 Mn |
| Mar 31, 2021 | 764.05 Mn |
| Dec 31, 2020 | 607.44 Mn |
| Sep 30, 2020 | 692.22 Mn |
| Jun 30, 2020 | 678.69 Mn |
| Mar 31, 2020 | 573.06 Mn |
| Dec 31, 2019 | 604.80 Mn |
| Sep 30, 2019 | 613.82 Mn |
| Jun 30, 2019 | 647.57 Mn |
| Mar 31, 2019 | 667.67 Mn |
| Dec 31, 2018 | 709.16 Mn |
| Sep 30, 2018 | 716.19 Mn |
| Jun 30, 2018 | 491.14 Mn |
| Mar 31, 2018 | 500.79 Mn |
| Dec 31, 2017 | 520.35 Mn |
| Sep 30, 2017 | 520.51 Mn |
| Jun 30, 2017 | 507.13 Mn |
| Mar 31, 2017 | 510.38 Mn |
| Dec 31, 2016 | 525.28 Mn |
| Sep 30, 2016 | 532.42 Mn |
| Jun 30, 2016 | 533.97 Mn |
| Mar 31, 2016 | 507.10 Mn |
| Dec 31, 2015 | 512.26 Mn |
| Sep 30, 2015 | 511.63 Mn |
| Jun 30, 2015 | 425.14 Mn |
| Mar 31, 2015 | 415.99 Mn |
| Dec 31, 2014 | 135.47 Mn |
| Sep 30, 2014 | 145.93 Mn |
| Dec 31, 2013 | 20.50 Mn |
| Sep 30, 2013 | 21.36 Mn |
| Mar 31, 2013 | 4.95 Mn |
| Nov 30, 2012 | 3,900.00 |
| Aug 31, 2012 | 3,900.00 |
| May 31, 2012 | 3,900.00 |
| Feb 29, 2012 | 3,909.00 |
| Nov 30, 2011 | 3.89 Mn |
| Aug 31, 2011 | 3,909.00 |
| Feb 28, 2011 | 3,958.00 |